Ludek Pour

Summary

Affiliation: University Hospital
Country: Czech Republic

Publications

  1. doi request reprint Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib
    Ludek Pour
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Clin Lymphoma Myeloma 9:151-3. 2009
  2. doi request reprint Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response
    Ludek Pour
    Departement of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Ann Hematol 89:385-9. 2010
  3. ncbi request reprint Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma
    L Pour
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University Brno Czech Republic
    Neoplasma 57:29-34. 2010
  4. ncbi request reprint Skin lesions induced by bortezomib
    Ludek Pour
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, Brno, 625 00, Czech Republic
    Haematologica 90:ECR44. 2005
  5. doi request reprint Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
    Pour Ludek
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Eur J Haematol 84:332-6. 2010
  6. doi request reprint Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
    Marta Krejci
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic
    Ann Hematol 90:1441-7. 2011
  7. doi request reprint Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse
    Marta Krejci
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, 625 00 Brno, Czech Republic
    Clin Lymphoma Myeloma 9:436-42. 2009
  8. doi request reprint IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen
    Zdenek Adam
    Department of Internal Medicine, Masaryk University, Brno, Czech Republic
    Wien Klin Wochenschr 122:311-4. 2010
  9. doi request reprint Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma
    Marta Krejci
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, Brno 62500, Czech Republic
    Ann Hematol 89:483-7. 2010
  10. doi request reprint Cytogenetics in multiple myeloma patients progressing into extramedullary disease
    Lenka Besse
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Eur J Haematol 97:93-100. 2016

Collaborators

Detail Information

Publications20

  1. doi request reprint Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib
    Ludek Pour
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Clin Lymphoma Myeloma 9:151-3. 2009
    ..The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population...
  2. doi request reprint Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response
    Ludek Pour
    Departement of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Ann Hematol 89:385-9. 2010
    ..VEGF and HGF levels decrease but those of TSP-1 increase after successful treatment for MM, indicating a reduction in the rate of angiogenesis...
  3. ncbi request reprint Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma
    L Pour
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University Brno Czech Republic
    Neoplasma 57:29-34. 2010
    ..Patients with low angiogenesis rate as determined by the relative HGF and TSP-1 concentrations were more likely to achieve complete or very good partial response after high-dose chemotherapy...
  4. ncbi request reprint Skin lesions induced by bortezomib
    Ludek Pour
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, Brno, 625 00, Czech Republic
    Haematologica 90:ECR44. 2005
    ..Therapy with prednisone led to rapid resolution of the skin lesions. Prednisone 10 mg before each infusion of bortezomib was necessary to prevent recurrence of the rash while antihistamines alone were ineffective...
  5. doi request reprint Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration
    Pour Ludek
    Department of Internal Medicine Hematooncology, University Hospital Brno, Masaryk University, Brno, Czech Republic
    Eur J Haematol 84:332-6. 2010
    ..High pretreatment thrombospondin and low pretreatment HGF concentrations are associated with therapeutic response to bortezomib in patients with MM...
  6. doi request reprint Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
    Marta Krejci
    Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic
    Ann Hematol 90:1441-7. 2011
    ..2 months. No significant differences in ORR (p=0.774), TTP (p=0.207), or OS (p=0.889) were observed between the two groups. In conclusion, T- and B-based regimens appear to be equally effective in the treatment of first MM relapse...
  7. doi request reprint Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse
    Marta Krejci
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, 625 00 Brno, Czech Republic
    Clin Lymphoma Myeloma 9:436-42. 2009
    ..Treatment options for myeloma have expanded in the past decade, and it seems that patients who are treated with novel drugs such as thalidomide and bortezomib for relapse after autoSCT have longer overall survival (OS)...
  8. doi request reprint IgA pemphigus associated with monoclonal gammopathy completely resolved after achievement of complete remission of multiple myeloma with bortezomib, cyclophosphamide and dexamethasone regimen
    Zdenek Adam
    Department of Internal Medicine, Masaryk University, Brno, Czech Republic
    Wien Klin Wochenschr 122:311-4. 2010
    ..This suggests that bortezomib-based therapy is useful for the treatment of the rare dermatologic disorder associated with IgA gammopathy...
  9. doi request reprint Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma
    Marta Krejci
    Department of Internal Medicine Hematooncology, Masaryk University Hospital, Jihlavska 20, Brno 62500, Czech Republic
    Ann Hematol 89:483-7. 2010
    ..Treatment with upfront MEL 100 followed by a thalidomide- or bortezomib-based regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM...
  10. doi request reprint Cytogenetics in multiple myeloma patients progressing into extramedullary disease
    Lenka Besse
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Eur J Haematol 97:93-100. 2016
    ....
  11. doi request reprint Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide
    Martina Almasi
    Babak Research Institute, Masaryk University, Brno, Czech Republic
    Clin Lymphoma Myeloma Leuk 11:414-20. 2011
    ..In that study, the researchers built a classification tree that enables prediction of individual risk of VTE in patients with MM...
  12. doi request reprint Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors
    Pavla Vsianska
    Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic
    Eur J Haematol 98:19-25. 2017
    ..Finding higher activity of ALDH in some cell subsets in monoclonal gammopathies (MG) could identify potential source of myeloma-initiating cells (MICs)...
  13. pmc Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma
    Lenka Besse
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
    PLoS ONE 10:e0137294. 2015
    ..0001). Together, our data suggest connection between lower level of microRNA-130a and extramedullary disease and prompt further work to evaluate this miRNA as a marker of extramedullary disease in multiple myeloma. ..
  14. doi request reprint Analysis of B-cell subpopulations in monoclonal gammopathies
    Pavla Vsianska
    Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic
    Clin Lymphoma Myeloma Leuk 15:e61-71. 2015
    ..To clarify its pathophysiology it is necessary to investigate in detail the developmental stages of B-cells...
  15. doi request reprint Extramedullary relapse of multiple myeloma defined as the highest risk group based on deregulated gene expression data
    Sabina Sevcikova
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:288-93. 2015
    ..Recently, extramedullary relapse of MM (EM) has been observed more frequently. Due to its aggressivity and shorter survival, EM is also considered high-risk...
  16. doi request reprint Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma
    Petr Szturz
    Department of Internal Medicine Hematooncology, Faculty of Medicine of Masaryk University and University Hospital Brno, Czech Republic
    Nucl Med Biol 39:429-36. 2012
    ....
  17. pmc Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma
    Lenka Kubiczkova
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic Department of Clinical Hematology, University Hospital Brno, Brno, Czech Republic
    J Cell Mol Med 18:947-61. 2014
    ..This review provides an overview of main mechanisms of action of PIs in MM, focusing on the ongoing development and progress of novel anti-proteasome therapeutics. ..
  18. doi request reprint Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy
    Pavel Nemec
    University Research Centre, Czech Myeloma Group, Masaryk University, Kamenice 5, Brno, Czech Republic
    Biol Blood Marrow Transplant 16:548-54. 2010
    ..We conclude that 1q21 gain defines a prognostically unfavorable group of MM patients...
  19. pmc Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment
    Karthick Raja Muthu Raja
    Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
    PLoS ONE 7:e49446. 2012
    ..In this study, we aimed to prove the presence of functionally suppressive Treg cells expressing CD8 phenotype (CD8 Treg cells) in MM. To the best of our knowledge, this has not been reported previously in MM...
  20. doi request reprint Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma
    Jaroslav Michalek
    University Cell Immunotherapy Centre, Masaryk University, Kamenice 5, Brno, Czech Republic
    Br J Haematol 148:859-67. 2010
    ..We conclude that the clonotypic assay is the most sensitive tool for immunomonitoring of low-frequency T cells...